Adagrasib

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Adagrasib
Oct 22, 2024, 08:02 | Insight
Stephen V Liu: Jennifer A. Marks updates on KRAS, sotorasib and adagrasib
Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared a post on X:…
Aug 11, 2024, 12:09 | Insight
Weekly digest breakthroughs in cancer treatment, chemistry, and more by The Babak Lab
Maria Babak shared a post by The Babak Lab, on LinkedIn adding: “Let's recap on…
Aug 5, 2024, 04:49 | Drugs
Maria Babak: Key highlight from The Babak Lab on FDA Approval for Adagrasib
Maria Babak shared a post by The Babak Lab on LinkedIn: "This FDA approval represents…
Jul 12, 2024, 14:18 | Blog
Updated review on targeting KRAS in NSCLC
Stephen V Liu shared on X: "Updated review on targeting KRAS in NSCLC available in…
Jul 12, 2024, 11:24 | Insight
What comes after sotorasib and adagrasib?
Aakash Desai, Thoracic/Phase 1 Oncologist at UAB O'Neal Comprehensive Cancer Center, shared a post on…
Jul 6, 2024, 13:16 | Blog
Wafik El-Deiry about DAVA Oncology 3rd Global Thoracic Malignancies Summit
Wafik El-Deiry shared posts on LinkedIn and X:  . "Grateful for opportunity to speak about…
Jul 1, 2024, 14:03 | Drugs
Robert Jotte presents how Adagrasib shows improvement in PFS and ORR in previously treated patients - Sarah Cannon Research Institute
Sarah Cannon Research Institute shared on LinkedIn: "Significant advancements in NSCLC treatment! SCRI's Dr. Robert Jotte…
Jun 27, 2024, 18:05 | Drugs
Adagrasib plus Cetuximab shows efficacy and safety in metastatic colorectal cancer
Iván R. González, Medical Oncologist at Centro Oncológico Integral, shared on X: "In the KRYSTAL-1…
Jun 27, 2024, 11:18 | Blog
FDA approves the targeted therapy adagrasib for people with advanced colorectal cancer - MSKCC
Memorial Sloan Kettering Cancer Center shared a post on LinkedIn: “The US Food and Drug…
Jun 25, 2024, 07:47 | Blog
Mark Lewis: It is UNACCEPTABLE to treat mCRC without knowing these biomarker
Mark Lewis shared a post by FDA Oncology on X, adding the following:   . “We…
Jun 22, 2024, 15:13 | Drugs
Vivek Subbiah: Another FDA approval to adagrasib plus cetuximab for KRAS G12C-mutated colorectal cancer
Vivek Subbiah shared on LinkedIn: "It's Friday and time for another FDA approval! FDA grants…
Jun 22, 2024, 14:35 | Drugs
FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer
FDA Oncology shared on X: "FDA grants accelerated approval to adagrasib with cetuximab for KRAS…
May 27, 2024, 04:19 | Opinion
Gilberto Lopes: My top ASCO24 lung cancer abstracts!
Gilberto Lopes, Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, shared…
Apr 11, 2024, 15:23 | Drugs
Piotr Wysocki: Adagrasib and cetuximab in KRAS G12C-mutated colorectal cancer is a safe and active
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Mar 29, 2024, 18:40 | Insight
Jarushka Naidoo: Ph III KRYSTAL-12 Trial of 2nd-line Adagrasib in KRAS G12C+ NSCLC meets primary PFS endpoint
Jarushka Naidoo shared on X/Twitter: "Ph III KRYSTAL-12 Trial of 2nd-line Adagrasib in KRAS G12C+…
All: 15 Posts: 1 - 100
Special Coverage